[Paravalvular aortic regurgitation after transcatheter aortic valve replacement].
Transcatheter aortic valve replacement (TAVR) is a rapidly evolving technology that has been accepted as a treatment option in patients with severe aortic stenosis who are not suitable for or are at high risk for conventional surgery. Randomized trials have shown that TAVR decreases mortality and improves quality of life in patients who are not suitable for conventional surgery and that TAVR is not inferior to standard surgery in operable but high- risk patients. However, TAVR has several important limitations, the most prominent of which is residual paravalvular aortic regurgitation (PAR). The purpose of this review is to present the mechanism, incidence, assessment, and treatment of PAR after TAVR.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Barış
B
Buğan
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Emin Murat
EM
Tuzcu
D001022:Aortic Valve Insufficiency; D017548:Echocardiography, Transesophageal; D006801:Humans; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects*